Analysis of cost per responder for the treatment of moderate to severe Psoriasis with biological agents
Latest Information Update: 18 Nov 2020
At a glance
- Drugs Adalimumab (Primary) ; Risankizumab (Primary) ; Apremilast; Etanercept; Guselkumab; Infliximab; Ixekizumab; Secukinumab; Ustekinumab
- Indications Psoriasis
- Focus Therapeutic Use
- 18 Nov 2020 New trial record
- 16 Nov 2020 Results presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research